Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
$0.37
+2.7%
$0.35
$0.22
$15.80
$18.34M0.797.11 million shs126,521 shs
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$9.63
-0.9%
$9.94
$3.08
$597.60
$15.03M0.08788,170 shs26,172 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$1.65
+0.7%
$1.39
$1.14
$3.00
$24.55M0.23294,780 shs13,375 shs
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
$0.14
$0.27
$0.10
$1.08
$6.29M1.191.73 million shs1,012 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
0.00%-27.88%+23.42%+36,039,900.00%+36,039,900.00%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
0.00%-39.40%+4,071.67%-86.45%-97.50%
Longeveron Inc. stock logo
LGVN
Longeveron
0.00%-2.10%+24.33%+9.00%-43.43%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00%-26.32%-53.33%+10.15%-86.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
0.2468 of 5 stars
0.02.00.00.01.11.70.0
Longeveron Inc. stock logo
LGVN
Longeveron
2.2768 of 5 stars
3.62.00.00.01.71.70.6
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.5203 of 5 stars
0.03.00.00.00.92.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
0.00
N/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
2.00
HoldN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
3.25
Buy$8.67426.53% Upside
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/AN/AN/AN/A($2.17) per shareN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
$40K380.39N/AN/A($58.87) per share-0.16
Longeveron Inc. stock logo
LGVN
Longeveron
$2.39M10.28N/AN/A$1.47 per share1.12
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/A($2.68) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
-$12.54MN/A0.00N/AN/AN/A-508.70%N/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
-$11.21M-$839.58N/AN/AN/A-3,648.09%-155.99%8/13/2025 (Estimated)
Longeveron Inc. stock logo
LGVN
Longeveron
-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
-$82.94M-$2.45N/AN/AN/AN/A-479.36%N/A

Latest NKGN, LGVN, CYCC, and ASBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Longeveron Inc. stock logo
LGVN
Longeveron
-$0.35N/AN/AN/A$0.41 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/AN/AN/AN/AN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/A
0.22
0.22
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
N/A
5.60
5.60
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
5.61
5.61
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A
0.02
0.02

Institutional Ownership

CompanyInstitutional Ownership
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
19.17%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
23.58%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
76.17%

Insider Ownership

CompanyInsider Ownership
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
48.00%
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
51.20%
Longeveron Inc. stock logo
LGVN
Longeveron
11.20%
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
10.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aspire Biopharma Holdings, Inc. stock logo
ASBP
Aspire Biopharma
N/A49.53 million25.75 millionN/A
Cyclacel Pharmaceuticals, Inc. stock logo
CYCC
Cyclacel Pharmaceuticals
141.58 million773,000Optionable
Longeveron Inc. stock logo
LGVN
Longeveron
2014.93 million13.26 millionNot Optionable
NKGen Biotech, Inc. stock logo
NKGN
NKGen Biotech
N/A44.95 million40.29 millionNot Optionable

Recent News About These Companies

NKGen Biotech Enters Stock Purchase Agreement
NKGen Biotech Chairman & CEO Paul Y. Song, M.D.
NKGen Biotech presents data from Phase 1/2a trial of troculeucel

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aspire Biopharma stock logo

Aspire Biopharma NASDAQ:ASBP

$0.37 +0.01 (+2.72%)
As of 09:52 AM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

Cyclacel Pharmaceuticals stock logo

Cyclacel Pharmaceuticals NASDAQ:CYCC

$9.63 -0.09 (-0.93%)
As of 10:10 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$1.65 +0.01 (+0.67%)
As of 10:10 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

NKGen Biotech stock logo

NKGen Biotech NYSE:NKGN

$0.14 0.00 (0.00%)
As of 09:30 AM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.